Tang Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Tang Capital Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-550,000	Closed	-$36M	–	129
2025 Q3	$36M	Buy	550,000 +400,000	+267%	+$19.5M	1.39%	20
2025 Q2	$5.93M	Hold	150,000	–	–	0.3%	76
2025 Q1	$4.53M	Hold	150,000	–	–	0.25%	77
2024 Q4	$5.24M	Hold	150,000	–	–	0.35%	68
2024 Q3	$6.01M	Hold	150,000	–	–	0.43%	65
2024 Q2	$7.15M	Hold	150,000	–	–	0.73%	44
2024 Q1	$6.5M	Sell	150,000 -50,000	-25%	-$2.38M	0.68%	50
2023 Q4	$10.1M	Hold	200,000	–	–	0.93%	30
2023 Q3	$9.07M	Hold	200,000	–	–	1.28%	24
2023 Q2	$8.21M	Hold	200,000	–	–	1.21%	31
2023 Q1	$7.15M	Hold	200,000	–	–	1.07%	32
2022 Q4	$7.55M	Hold	200,000	–	–	1.1%	26
2022 Q3	$8.85M	Hold	200,000	–	–	1.08%	26
2022 Q2	$7.4M	Hold	200,000	–	–	1.12%	24
2022 Q1	$7.41M	Buy	+200,000	New	+$6.55M	1.48%	20

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Tang Capital Management's IONS Position: Q4 2025 in Review

Tang Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q4 2025, closing a stake of 550,000 shares — an estimated $36M sold.

Tang Capital Management first reported a position in IONS in Q1 2022 and held it in 15 quarters. The position peaked at $36M in Q3 2025. 491 funds tracked by Wall St. Rank hold IONS as of Q4 2025.

Tang Capital Management reported no remaining Ionis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Tang Capital Management sold 550,000 Ionis Pharmaceuticals shares in Q4 2025, an estimated $36M.
Tang Capital Management first reported a position in Ionis Pharmaceuticals in Q1 2022 and held it in 15 quarters.
Tang Capital Management's Ionis Pharmaceuticals position peaked at $36M in Q3 2025.
491 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2025.

Based on Tang Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.